Paraganglioma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Clinical Trials

Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
Conditions:   Neuroendocrine Tumor;   Anaplastic Thyroid Cancer;   Adenocarcinoma;   Pheochromocytoma;   Paraganglioma Intervention:   Drug: Cabozantinib 40 mg Sponsors:   Grupo Espanol de Tumores Neuroendocrinos;   Ipsen;   Roche Pharma AG Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 25, 2020 Category: Research Source Type: clinical trials